RU2010114021A - Субстанция р и тиролиберин для терапевтического применения - Google Patents
Субстанция р и тиролиберин для терапевтического применения Download PDFInfo
- Publication number
- RU2010114021A RU2010114021A RU2010114021/15A RU2010114021A RU2010114021A RU 2010114021 A RU2010114021 A RU 2010114021A RU 2010114021/15 A RU2010114021/15 A RU 2010114021/15A RU 2010114021 A RU2010114021 A RU 2010114021A RU 2010114021 A RU2010114021 A RU 2010114021A
- Authority
- RU
- Russia
- Prior art keywords
- pro
- gln
- phe
- disease
- diseases
- Prior art date
Links
- 239000000126 substance Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 8
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract 5
- 206010016654 Fibrosis Diseases 0.000 claims abstract 5
- 208000019693 Lung disease Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 230000004761 fibrosis Effects 0.000 claims abstract 5
- 208000019622 heart disease Diseases 0.000 claims abstract 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 5
- 208000019553 vascular disease Diseases 0.000 claims abstract 5
- 230000030833 cell death Effects 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 4
- 208000015181 infectious disease Diseases 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 208000030507 AIDS Diseases 0.000 claims abstract 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims abstract 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims abstract 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims abstract 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims abstract 2
- 206010025327 Lymphopenia Diseases 0.000 claims abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims abstract 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims abstract 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims abstract 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 2
- 231100000836 acute liver failure Toxicity 0.000 claims abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract 2
- 239000000872 buffer Substances 0.000 claims abstract 2
- 230000007812 deficiency Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 210000002919 epithelial cell Anatomy 0.000 claims abstract 2
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 claims abstract 2
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 208000000509 infertility Diseases 0.000 claims abstract 2
- 230000036512 infertility Effects 0.000 claims abstract 2
- 231100000535 infertility Toxicity 0.000 claims abstract 2
- 230000000302 ischemic effect Effects 0.000 claims abstract 2
- 210000003734 kidney Anatomy 0.000 claims abstract 2
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims abstract 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims abstract 2
- 241000712461 unidentified influenza virus Species 0.000 claims abstract 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- -1 lyoprotector Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
Abstract
1. Сочетание пептидов Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 и Pyr-His-Pro-NH2 или их солей или гидратов. ! 2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%. ! 3. Сочетание по п.1 для применения в медицине. ! 4. Применение пептида Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов. ! 5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, инфекционное заболевание, заболевание легких или заболевание сердца и сосудов выбраны из СПИДа, болезни Альцгеймера, бокового амиотрофического склероза, ишемического повреждения почки, пигментного ретинита, апластической анемии, миелодиспластического синдрома, CD4+ T-клеточной лимфоцитопении, дефицита Г6ФДГ, инфаркта миокарда, инсульта, поликистозной почки, острой печеночной недостаточности, острого тубулярного некроза, бесплодия, индуцированной Streptococcus pneumoniae гибели эпителиальных клеток и индуцированной вирусом гриппа гибели клеток. ! 6. Применение пептида Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 7. Применение пептида Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 для получения лиофилизированного состава или буферного жидкого состава. ! 8. Фармацевтическая композиция, содержащая сочетание по п.1, по меньшей мере, совместно с одним фармацевтически прием�
Claims (12)
1. Сочетание пептидов Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 и Pyr-His-Pro-NH2 или их солей или гидратов.
2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%.
3. Сочетание по п.1 для применения в медицине.
4. Применение пептида Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов.
5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, инфекционное заболевание, заболевание легких или заболевание сердца и сосудов выбраны из СПИДа, болезни Альцгеймера, бокового амиотрофического склероза, ишемического повреждения почки, пигментного ретинита, апластической анемии, миелодиспластического синдрома, CD4+ T-клеточной лимфоцитопении, дефицита Г6ФДГ, инфаркта миокарда, инсульта, поликистозной почки, острой печеночной недостаточности, острого тубулярного некроза, бесплодия, индуцированной Streptococcus pneumoniae гибели эпителиальных клеток и индуцированной вирусом гриппа гибели клеток.
6. Применение пептида Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
7. Применение пептида Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 для получения лиофилизированного состава или буферного жидкого состава.
8. Фармацевтическая композиция, содержащая сочетание по п.1, по меньшей мере, совместно с одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
9. Фармацевтическая композиция по п.8 в форме лиофилизата или жидкого буферного раствора.
10. Фармацевтическая композиция по п.8 или 9, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
11. Фармацевтическая композиция по п.8 или 9 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
12. Фармацевтическая композиция по п.8 или 9, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезни обмена веществ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017754.8 | 2007-09-11 | ||
| EP07017754 | 2007-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010114021A true RU2010114021A (ru) | 2011-10-20 |
Family
ID=40085520
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113975/15A RU2010113975A (ru) | 2007-09-11 | 2008-09-09 | (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА |
| RU2010113987/15A RU2010113987A (ru) | 2007-09-11 | 2008-09-09 | ПРИМЕНЕНИЕ BFGF 1-24 И НЕОБЯЗАТЕЛЬНО (Arg 8) ВАЗОПРЕССИНА ДЛЯ ЛЕЧЕНИЯ, НАПРИМЕР, ИНФЕКЦИИ S. PNEUMONIAE |
| RU2010114001/15A RU2010114001A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
| RU2010113983/15A RU2010113983A (ru) | 2007-09-11 | 2008-09-09 | Применение туфтсина в качестве терапевтического средства |
| RU2010114021/15A RU2010114021A (ru) | 2007-09-11 | 2008-09-09 | Субстанция р и тиролиберин для терапевтического применения |
| RU2010113964/15A RU2010113964A (ru) | 2007-09-11 | 2008-09-09 | Применение соматостатина-14 в качестве терапевтического средства |
| RU2010113965/10A RU2010113965A (ru) | 2007-09-11 | 2008-09-09 | Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства |
| RU2010114033/15A RU2010114033A (ru) | 2007-09-11 | 2008-09-09 | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113975/15A RU2010113975A (ru) | 2007-09-11 | 2008-09-09 | (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА |
| RU2010113987/15A RU2010113987A (ru) | 2007-09-11 | 2008-09-09 | ПРИМЕНЕНИЕ BFGF 1-24 И НЕОБЯЗАТЕЛЬНО (Arg 8) ВАЗОПРЕССИНА ДЛЯ ЛЕЧЕНИЯ, НАПРИМЕР, ИНФЕКЦИИ S. PNEUMONIAE |
| RU2010114001/15A RU2010114001A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
| RU2010113983/15A RU2010113983A (ru) | 2007-09-11 | 2008-09-09 | Применение туфтсина в качестве терапевтического средства |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113964/15A RU2010113964A (ru) | 2007-09-11 | 2008-09-09 | Применение соматостатина-14 в качестве терапевтического средства |
| RU2010113965/10A RU2010113965A (ru) | 2007-09-11 | 2008-09-09 | Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства |
| RU2010114033/15A RU2010114033A (ru) | 2007-09-11 | 2008-09-09 | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv |
Country Status (8)
| Country | Link |
|---|---|
| US (8) | US20100210567A1 (ru) |
| EP (8) | EP2197480A2 (ru) |
| JP (7) | JP2010538995A (ru) |
| KR (7) | KR20100058558A (ru) |
| AU (8) | AU2008303942A1 (ru) |
| CA (8) | CA2698768A1 (ru) |
| RU (8) | RU2010113975A (ru) |
| WO (19) | WO2009033805A2 (ru) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1697035B1 (en) * | 2003-12-22 | 2017-11-15 | Warren H. Finlay | Powder formation by atmospheric spray-freeze drying |
| EP1759001B1 (en) | 2004-04-21 | 2011-04-13 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| EP2197465A2 (en) * | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| WO2009083844A1 (en) | 2007-12-20 | 2009-07-09 | Koninklijke Philips Electronics N.V. | Method and device for case-based decision support |
| JP5646459B2 (ja) | 2008-05-14 | 2014-12-24 | アグリカルチャー ヴィクトリア サービス ピーティーワイ エルティーディーＡｇｒｉｃｕｌｔｕｒｅ Ｖｉｃｔｏｒｉａ Ｓｅｒｖｉｃｅｓ Ｐｔｙ Ｌｔｄ | 疾患及び障害を治療するためのアンギオゲニン又はアンギオゲニンアゴニストの使用 |
| AU2013204721B2 (en) * | 2008-05-14 | 2016-08-18 | Agriculture Victoria Services Pty Ltd | Methods for treating cachexia |
| WO2011047287A1 (en) * | 2009-10-15 | 2011-04-21 | Immuneregen Biosciences, Inc. | Methods of treating inflammatory and fibrotic lung diseases with substance p analogs |
| AU2011350066A1 (en) | 2010-12-27 | 2013-07-11 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| EP2476441A1 (en) | 2011-01-13 | 2012-07-18 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
| SG187271A1 (en) * | 2011-07-07 | 2013-02-28 | Agency Science Tech & Res | Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic |
| US10272133B2 (en) | 2011-10-06 | 2019-04-30 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| KR101327663B1 (ko) * | 2011-10-07 | 2013-11-14 | 중앙대학교 산학협력단 | 안지오제닌의 신규 용도 |
| WO2013051767A1 (ko) * | 2011-10-06 | 2013-04-11 | 중앙대학교 산학협력단 | 안지오제닌의 신규 용도 |
| US9044433B2 (en) | 2011-10-06 | 2015-06-02 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| CN102973926A (zh) * | 2011-11-20 | 2013-03-20 | 上海市肺科医院 | 胸腺肽α1在制备治疗肺纤维化药物中的用途 |
| JP2015502368A (ja) * | 2011-12-16 | 2015-01-22 | カロス セラピューティクス，インコーポレーテッド | 網膜の障害および疾患の治療のためのａｎｐ（心房性ナトリウム利尿ペプチド）、ｂｎｐ（脳性ナトリウム利尿ペプチド）およびｃｎｐ（ｃ型ナトリウム利尿ペプチド）−関連ペプチドならびにそれらの誘導体の方法および使用 |
| WO2013133325A1 (ja) | 2012-03-06 | 2013-09-12 | 武田薬品工業株式会社 | 三環性化合物 |
| RU2507212C3 (ru) * | 2012-03-28 | 2022-05-04 | Общество С Ограниченной Ответственностью "Айвикс" | Способ получения рекомбинантного пептида и полученный пептид |
| AU2013204740C1 (en) * | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US9403874B2 (en) | 2012-07-03 | 2016-08-02 | Samsung Life Public Welfare Foundation | Peptides and use thereof |
| WO2014021942A1 (en) * | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
| RU2528094C2 (ru) * | 2012-08-03 | 2014-09-10 | Татьяна Георгиевна Емельянова | Средство пептидной структуры, обладающее анальгетическим, противовоспалительным действием, и лекарственные формы на его основе |
| AU2013312819A1 (en) * | 2012-09-04 | 2015-03-26 | Lauren Sciences Llc | Bolaamphiphilic compounds, compositions and uses thereof |
| AU2014213631B2 (en) | 2013-02-05 | 2018-03-08 | Tpcera Ltd | Phosphorylcholine conjugates and uses thereof |
| US10046021B2 (en) | 2013-02-05 | 2018-08-14 | Tpcera Ltd. | Phosphorylcholine conjugates and uses thereof |
| WO2020056250A1 (en) * | 2018-09-14 | 2020-03-19 | Vanderbilt University | Methods and compositions for treating skin diseases |
| US9492544B2 (en) | 2013-04-11 | 2016-11-15 | Vanderbilt University | Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders |
| US11571455B2 (en) | 2013-04-11 | 2023-02-07 | Vanderbilt University | Methods and compositions for treating alcoholic liver disease |
| JP6552960B2 (ja) * | 2013-05-28 | 2019-07-31 | アイビックス・リミテッドＩｖｉｘ Ｌｔｄ． | 組換えペプチドを生産するための方法および得られるペプチド |
| CN103613643B (zh) * | 2013-12-04 | 2015-04-22 | 南京晓庄学院 | 一种生物活性小肽、其合成方法及其作为畜禽饲料添加剂的用途 |
| US20150335712A1 (en) | 2014-05-21 | 2015-11-26 | Stemnion, Inc. | Treatment of Diseases and Conditions Caused by Increased Vascular Permeability |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| KR20170095278A (ko) | 2014-12-05 | 2017-08-22 | 알렉시온 파마슈티칼스, 인코포레이티드 | 재조합 알칼리성 포스파타제를 이용한 발작 치료 |
| DE102015201100B4 (de) * | 2015-01-22 | 2018-05-17 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Antivirale Mittel |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| AU2016308624B2 (en) | 2015-08-17 | 2022-06-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| EP3436052A4 (en) | 2016-04-01 | 2019-10-09 | Alexion Pharmaceuticals, Inc. | TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES |
| WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
| JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 気管気管支軟化症の治療方法 |
| RU2626002C1 (ru) | 2016-10-24 | 2017-07-21 | Общество С Ограниченной Ответственностью "Айвикс" | Новая группа пептидов для лечения женской сексуальной дисфункции |
| EP3573637A4 (en) * | 2017-01-27 | 2020-11-11 | Vanderbilt University | NUCLEAR FUS TRANSLOCATION INHIBITORS FOR THE TREATMENT OF FIBROSIS |
| EP3590527A4 (en) | 2017-03-01 | 2021-01-06 | Chengdu Huitai Biomedicine Co., Ltd. | POLYPEPTIDE, POLYPEPTIDE FRAGMENT, DERIVATIVE THEREOF AND APPLICATIONS THEREOF |
| CN106860855B (zh) * | 2017-03-01 | 2021-06-11 | 成都惠泰生物医药有限公司 | 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用 |
| BR112019020506A2 (pt) | 2017-03-31 | 2020-08-04 | Alexion Pharmaceuticals, Inc. | métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes |
| EP3717504A4 (en) * | 2017-11-27 | 2021-10-20 | The University of Hong Kong | YEAT INHIBITORS AND THEIR METHODS OF USE |
| EP3773684A1 (en) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
| EP3773497B1 (en) * | 2018-04-09 | 2023-10-18 | Elgan Pharma Ltd. | Oxytocin compositions and methods of use |
| US20210346462A1 (en) * | 2018-10-04 | 2021-11-11 | Rutgers, The State University Of New Jersey | Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides |
| CN112386678B (zh) * | 2019-08-13 | 2023-07-07 | 成都惠泰生物医药有限公司 | 多肽或其衍生物的应用 |
| US20240066157A1 (en) * | 2021-01-05 | 2024-02-29 | Jaya Shukla | Molecular imaging complex for positron emission tomography |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3778426A (en) * | 1970-12-16 | 1973-12-11 | Research Corp | Therapeutically useful polypeptides |
| US4041155A (en) * | 1974-10-29 | 1977-08-09 | American Home Products Corporation | Long acting somatostatin composition |
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4235988A (en) | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
| US4125605A (en) * | 1977-10-19 | 1978-11-14 | The United States Government | Method of employing oral TRH |
| EP0035454A3 (en) * | 1980-02-28 | 1982-03-03 | Genentech, Inc. | Desacetylthymosin alpha 1, its process of preparation and its use |
| US4481139A (en) * | 1983-04-13 | 1984-11-06 | Board Of Regents, The University Of Texas System | Peptide antagonists of substance P |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US4705778A (en) * | 1985-10-22 | 1987-11-10 | Sri International | Orally active LHRH analogs |
| US5691310A (en) * | 1987-09-29 | 1997-11-25 | Vesely; David L. | Methods of treatment using proANF peptides |
| SE8803847A0 (sv) * | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulerande peptid |
| US5432176A (en) * | 1988-11-29 | 1995-07-11 | The John Hopkins University | Method of retarding the progression of chronic renal failure |
| US5118670A (en) * | 1988-12-14 | 1992-06-02 | Massachusetts Institute Of Technology | Process and composition for increasing brain dopamine release |
| US4874744A (en) * | 1989-03-13 | 1989-10-17 | University Of Cincinnati | Method of using melanocyte stimulating hormone as dermatis treatment |
| US5217955A (en) * | 1989-09-15 | 1993-06-08 | Biomeasure, Inc. | Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin |
| US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
| JP3130080B2 (ja) * | 1990-12-27 | 2001-01-31 | 日清製粉株式会社 | ペプチドおよびその製造方法 |
| DE69128283T2 (de) | 1991-08-12 | 1998-03-19 | Nestle Sa | Nahrungsmittelzusammensetzung |
| US5308833A (en) * | 1992-02-06 | 1994-05-03 | Sciclone Pharmaceuticals | Method for treating hepatitis B carriers with minimal disease |
| WO1994005313A1 (en) * | 1992-08-31 | 1994-03-17 | Magainin Pharmaceuticals Inc. | Treatment of gynecological malignancies with biologically active peptides |
| US6200952B1 (en) * | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
| DE69429450T2 (de) * | 1993-09-24 | 2002-07-25 | University Of Southern California, Los Angeles | Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung |
| US5449761A (en) * | 1993-09-28 | 1995-09-12 | Cytogen Corporation | Metal-binding targeted polypeptide constructs |
| WO1995030418A1 (en) * | 1994-05-09 | 1995-11-16 | The Johns Hopkins University | Method of slowing the progression of hiv infection |
| US6495518B1 (en) * | 1994-06-13 | 2002-12-17 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US7553929B2 (en) * | 1994-06-13 | 2009-06-30 | Vanderbilt University | Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| ATE237362T1 (de) | 1996-02-19 | 2003-05-15 | Amersham Health As | Thermostabilisiertes kontrastmittel |
| JPH09227590A (ja) * | 1996-02-27 | 1997-09-02 | Nisshin Flour Milling Co Ltd | ペプチド |
| US5691314A (en) * | 1996-03-18 | 1997-11-25 | The Medical College Of Hampton Roads | Adjunctive therapy |
| TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
| US6492330B1 (en) * | 1996-08-16 | 2002-12-10 | National Institute Of Immunology | Antiangiogenic drugs |
| EP0832565B1 (fr) | 1996-09-24 | 2000-06-07 | Societe Des Produits Nestle S.A. | Substitut de lait et procédé de fabrication |
| US5830434A (en) * | 1997-02-26 | 1998-11-03 | Medical University Of South Carolina Foundation For Research Development | Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide |
| SE9701162D0 (sv) * | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
| WO1999003491A1 (en) * | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | New use of nociceptin |
| CA2319701C (en) * | 1998-02-09 | 2009-09-29 | University Of Southern California | Method of promoting erythropoiesis |
| SE9801571D0 (sv) * | 1998-05-05 | 1998-05-05 | Wapharm Ab | Melanokortin-1-receptorselektiva föreningar |
| US6333313B1 (en) * | 1998-10-29 | 2001-12-25 | Board Of Regents, The University Of Texas System | Clinical use of oxytocin alone or in combination to treat bone disorders |
| DE69919019T2 (de) | 1998-11-24 | 2004-11-25 | Société des Produits Nestlé S.A. | Verfahren zur Herstellung einer Proteinzusammensetzung und einer diese enthaltenden Säuglingsnahrung |
| WO2000043500A2 (en) * | 1999-01-21 | 2000-07-27 | Vitro Diagnostics, Inc. | Immortalized cell lines and methods of making the same |
| US20040013641A1 (en) | 1999-04-15 | 2004-01-22 | Monash University | Disease prevention by reactivation of the thymus |
| US6313370B1 (en) * | 1999-04-29 | 2001-11-06 | Morton Hyson | Medicated wrap |
| US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| PT1105409E (pt) * | 1999-05-17 | 2006-07-31 | Conjuchem Inc | Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue |
| CA2375148A1 (en) * | 1999-06-04 | 2000-12-14 | Novo Nordisk A/S | Compositions for the treatment of the catabolic state of prolonged critical illness |
| US6894026B1 (en) * | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| SE0001440D0 (sv) * | 2000-04-18 | 2000-04-18 | Entretech Medical Ab | A drug against climacteric disorders |
| WO2001080830A2 (en) * | 2000-04-21 | 2001-11-01 | Advanced Research And Technology Institute, Inc. | Pharmacotherapeutic process and composition for central nervous system disorders |
| EP1296704A4 (en) * | 2000-06-14 | 2005-04-27 | Chanda Bhuwalka Zaveri | PEPTIDES WITH PHYSIOLOGICAL ACTIVITY |
| AU2001269439A1 (en) | 2000-07-05 | 2002-01-14 | Takeda Chemical Industries Ltd. | Medicinal preparations for treating sex hormone-dependent diseases |
| JP2004509079A (ja) * | 2000-08-02 | 2004-03-25 | セラテクノロジーズ・インコーポレーテッド | 効力が増大した修飾生体ペプチド |
| JP4817281B2 (ja) * | 2000-08-31 | 2011-11-16 | 塩野義製薬株式会社 | パーキンソン病治療剤 |
| WO2002102835A2 (en) * | 2000-11-21 | 2002-12-27 | New England Medical Center | Novel antimicrobial compounds |
| US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| SE0100684D0 (sv) * | 2001-02-28 | 2001-02-28 | Kerstin Uvnaes Moberg | New subject-matter |
| US7019109B2 (en) * | 2001-03-16 | 2006-03-28 | The Salk Institute For Bilogical Studies | SSTR1-selective analogs |
| US6682753B2 (en) * | 2001-03-23 | 2004-01-27 | Neuronz Limited | Methods for promoting weight gain using GPE-related compounds |
| CA2444626A1 (en) * | 2001-04-18 | 2002-10-31 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
| CN1317030C (zh) * | 2001-04-30 | 2007-05-23 | 赞塔里斯有限公司 | 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病 |
| US8633150B2 (en) * | 2001-05-16 | 2014-01-21 | Tni Biotech, Inc. | Methods for inducing sustained immune response |
| WO2006127702A2 (en) * | 2005-05-23 | 2006-11-30 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| WO2002096934A1 (en) * | 2001-05-25 | 2002-12-05 | Kemia, Inc. | Non-natural galanin receptor ligands |
| GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| SE0102910D0 (sv) * | 2001-08-31 | 2001-08-31 | Moberg Kerstin Uvnaes | New use |
| AU2002331816A1 (en) * | 2001-09-05 | 2003-03-18 | Anna P. Catania | A cancer treatment system |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| DE60128572T2 (de) | 2001-11-23 | 2008-02-07 | Société des Produits Nestlé S.A. | Verfahren zur Herstellung von Milchpulver und konzentrierten Milchprodukten |
| CA2391118A1 (en) * | 2002-06-21 | 2003-12-21 | Universite Du Quebec A Montreal | Oxytocin as cardiomyogenesis inducer and uses thereof |
| US7655772B2 (en) * | 2002-09-06 | 2010-02-02 | University Of South Florida | Materials and methods for treatment of allergic diseases |
| IL152289A0 (en) * | 2002-10-14 | 2003-05-29 | Vectabiotics Ltd | Method and composition for inhibiting h.pylori infection in a mammalian tissue |
| WO2004043396A2 (en) * | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
| US8309117B2 (en) * | 2002-12-19 | 2012-11-13 | Novartis, Ag | Method for making medical devices having antimicrobial coatings thereon |
| EP1608318A4 (en) * | 2003-03-27 | 2009-07-29 | Univ Emory | CXCR4 ANTAGONISTS AND METHODS OF USE |
| EP1663282A4 (en) * | 2003-09-24 | 2007-09-19 | Vecta Ltd | ORAL COMPOSITIONS FOR STIMULATING MAGNESIC ACID DETERRECTION WITH PENTAAGASTRINE |
| WO2005081687A2 (en) * | 2003-09-30 | 2005-09-09 | Centocor, Inc. | Human hinge core mimetibodies, compositions, methods and uses |
| EP1522311A1 (fr) * | 2003-10-10 | 2005-04-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée |
| JP2007509169A (ja) * | 2003-10-23 | 2007-04-12 | ニューレン ファーマシューティカルズ リミテッド | 静脈内注入後のＧｌｙ−Ｐｒｏ−Ｇｌｕの神経保護効果 |
| US20070053954A1 (en) * | 2003-10-24 | 2007-03-08 | Rowe Stephen C | Macromer-melt formulations |
| AU2005227870A1 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
| US7776815B2 (en) * | 2004-02-24 | 2010-08-17 | Wisconsin Alumni Research Foundation | Use of neuropeptides for ligament healing |
| CA2560956A1 (en) * | 2004-03-29 | 2005-10-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Amphipathic glycopeptides |
| WO2005097161A2 (en) * | 2004-03-30 | 2005-10-20 | Neuren Pharmaceuticals Limited | Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury |
| US7462595B2 (en) * | 2004-09-17 | 2008-12-09 | Prange Jr Arthur Jergen | Methods for treating cancer-related fatigue |
| AU2005319578A1 (en) * | 2004-11-24 | 2006-06-29 | Neopro Labs, Llc | Methods and compositions for treating conditions |
| WO2006063596A2 (en) * | 2004-12-15 | 2006-06-22 | Aditech Pharma Ab | A composition comprising pp for the treatment of gastrointestinal disorders |
| BRPI0606943A2 (pt) * | 2005-02-09 | 2009-07-28 | Da Volterra | fornecimento no cólon de agentes ativos |
| US20060205642A1 (en) * | 2005-03-08 | 2006-09-14 | Vesely David L | Oral methods of treatment using proANF peptides |
| EP1773870B1 (en) | 2005-05-03 | 2009-12-16 | Novetide Ltd. | Methods for the production of peptide having a c-terminal amide |
| AU2006282799B2 (en) * | 2005-08-26 | 2012-11-29 | Healthpartners Research & Education | Methods for treatment of headaches by administration of oxytocin |
| US20090069233A1 (en) * | 2005-09-13 | 2009-03-12 | Abburi Ramaiah | Agonist Peptides of Basic Fibroblast Growth Factor (bFGF) and the Method of Reduction of Wrinkles on Skin, Darkening of Hair and Acceleration of Wound Healing |
| US7601361B2 (en) * | 2005-10-03 | 2009-10-13 | E. I. Du Pont De Nemours And Company | Process for providing antimicrobial surfaces |
| WO2007044998A1 (en) * | 2005-10-12 | 2007-04-19 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
| US20070197445A1 (en) * | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
| EP1984546A4 (en) * | 2006-01-24 | 2009-09-23 | Univ British Columbia | POLYMORPHISMS OF THE VASOPRESSIN SIGNALING PATH AS INDICATORS OF THE EVOLUTION OF STATUS OF SUBJECTS IN SUBJECTS SERIOUSLY REACHED |
| BRPI0708773B1 (pt) | 2006-03-10 | 2021-10-19 | Laboswiss Ag | Método para solubilização, dispersão e estabilização de substâncias, produtos manufaturados de acordo com o método, bem como uso dos mesmos |
| EP2015765A4 (en) * | 2006-03-28 | 2011-11-23 | Neopro Labs Llc | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS |
| US20070238661A1 (en) * | 2006-04-11 | 2007-10-11 | Witten Mark L | Substance P treatment for hepatitis C |
| JP2009536670A (ja) * | 2006-05-10 | 2009-10-15 | スミスクライン・ビーチャム・コーポレイション | 化合物の細胞浸透性を増加させるための組成物および方法 |
| WO2008052043A2 (en) * | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| EP2081557A1 (en) * | 2006-11-17 | 2009-07-29 | DA Volterra | Colonic delivery using zn/pectin beads with a eudragit coating. |
-
2008
- 2008-09-09 AU AU2008303942A patent/AU2008303942A1/en not_active Abandoned
- 2008-09-09 AU AU2008303928A patent/AU2008303928A1/en not_active Abandoned
- 2008-09-09 JP JP2010523368A patent/JP2010538995A/ja active Pending
- 2008-09-09 CA CA2698768A patent/CA2698768A1/en not_active Abandoned
- 2008-09-09 EP EP08785859A patent/EP2197480A2/en not_active Withdrawn
- 2008-09-09 AU AU2008303945A patent/AU2008303945A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005665A patent/KR20100058558A/ko not_active Application Discontinuation
- 2008-09-09 JP JP2010523362A patent/JP2010538989A/ja active Pending
- 2008-09-09 CA CA2698821A patent/CA2698821A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005588A patent/KR20100058547A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/008133 patent/WO2009033805A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007531 patent/WO2009039983A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007500 patent/WO2009039966A2/en active Application Filing
- 2008-09-09 EP EP08802602A patent/EP2190535B1/en not_active Not-in-force
- 2008-09-09 WO PCT/EP2008/008130 patent/WO2009033802A2/en active Application Filing
- 2008-09-09 RU RU2010113975/15A patent/RU2010113975A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007628 patent/WO2009043455A2/en active Application Filing
- 2008-09-09 RU RU2010113987/15A patent/RU2010113987A/ru not_active Application Discontinuation
- 2008-09-09 RU RU2010114001/15A patent/RU2010114001A/ru not_active Application Discontinuation
- 2008-09-09 CA CA2698764A patent/CA2698764A1/en not_active Abandoned
- 2008-09-09 RU RU2010113983/15A patent/RU2010113983A/ru not_active Application Discontinuation
- 2008-09-09 US US12/677,311 patent/US20100210567A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/008029 patent/WO2009046863A2/en active Application Filing
- 2008-09-09 CA CA2699010A patent/CA2699010A1/en not_active Abandoned
- 2008-09-09 JP JP2010523348A patent/JP2010538977A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007529 patent/WO2009039981A2/en active Application Filing
- 2008-09-09 AU AU2008297928A patent/AU2008297928A1/en not_active Abandoned
- 2008-09-09 JP JP2010523426A patent/JP2010539053A/ja active Pending
- 2008-09-09 EP EP08802060A patent/EP2197469A2/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007991 patent/WO2009033793A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007604 patent/WO2009043437A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007433 patent/WO2009033658A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007739 patent/WO2009040030A1/en active Application Filing
- 2008-09-09 KR KR1020107005624A patent/KR20100059860A/ko not_active Application Discontinuation
- 2008-09-09 JP JP2010523360A patent/JP2010538987A/ja active Pending
- 2008-09-09 RU RU2010114021/15A patent/RU2010114021A/ru unknown
- 2008-09-09 CA CA2699264A patent/CA2699264A1/en not_active Abandoned
- 2008-09-09 AU AU2008297948A patent/AU2008297948A1/en not_active Abandoned
- 2008-09-09 US US12/676,925 patent/US20100204148A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007528 patent/WO2009039980A2/en active Application Filing
- 2008-09-09 EP EP08801996A patent/EP2187919A1/en not_active Withdrawn
- 2008-09-09 EP EP08835641A patent/EP2205261A1/en not_active Withdrawn
- 2008-09-09 AU AU2008306140A patent/AU2008306140A1/en not_active Abandoned
- 2008-09-09 RU RU2010113964/15A patent/RU2010113964A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/008003 patent/WO2009040084A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/008111 patent/WO2009043528A1/en active Application Filing
- 2008-09-09 EP EP08802090A patent/EP2187951A2/en not_active Withdrawn
- 2008-09-09 US US12/677,313 patent/US20100210534A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005622A patent/KR20100057054A/ko not_active Application Discontinuation
- 2008-09-09 US US12/677,762 patent/US20100204143A1/en not_active Abandoned
- 2008-09-09 JP JP2010523439A patent/JP5384502B2/ja not_active Expired - Fee Related
- 2008-09-09 US US12/676,906 patent/US20100286028A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005582A patent/KR20100056508A/ko not_active Application Discontinuation
- 2008-09-09 KR KR1020107005583A patent/KR20100056509A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007848 patent/WO2009046834A2/en active Application Filing
- 2008-09-09 AU AU2008297417A patent/AU2008297417A1/en not_active Abandoned
- 2008-09-09 CA CA2699215A patent/CA2699215A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007989 patent/WO2009033792A2/en active Application Filing
- 2008-09-09 US US12/676,907 patent/US20100273700A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005658A patent/KR20100075439A/ko not_active Application Discontinuation
- 2008-09-09 JP JP2010523367A patent/JP2010538994A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007470 patent/WO2009033678A2/en active Application Filing
- 2008-09-09 CA CA2731204A patent/CA2731204A1/en not_active Abandoned
- 2008-09-09 EP EP08802030A patent/EP2187920A2/en not_active Withdrawn
- 2008-09-09 CA CA2699100A patent/CA2699100A1/en not_active Abandoned
- 2008-09-09 EP EP08802483A patent/EP2187943A2/en not_active Withdrawn
- 2008-09-09 AU AU2008297567A patent/AU2008297567A1/en not_active Abandoned
- 2008-09-09 US US12/677,815 patent/US20100190722A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007933 patent/WO2009046849A1/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007602 patent/WO2009040006A1/en active Application Filing
- 2008-09-09 RU RU2010113965/10A patent/RU2010113965A/ru not_active Application Discontinuation
- 2008-09-09 US US12/677,813 patent/US8211856B2/en not_active Expired - Fee Related
- 2008-09-09 RU RU2010114033/15A patent/RU2010114033A/ru not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010114021A (ru) | Субстанция р и тиролиберин для терапевтического применения | |
| RU2010114015A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113982A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113997A (ru) | Тиролиберин для терапевтического применения | |
| RU2010114043A (ru) | Применение бета-меланотропина в качестве терапевтического средства, например, для лечения спид или болезни альцгеймера | |
| RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
| RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114045A (ru) | Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств | |
| RU2010114007A (ru) | Применение комбинации пептидов cart в качестве терапевтического средства | |
| RU2010114000A (ru) | Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства | |
| RU2010114002A (ru) | Применение фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
| RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
| RU2010113992A (ru) | Применение урокортина и кортиколиберина в качестве терапевтических средств | |
| RU2010113999A (ru) | Применение секретина и необязательно уродилатина в качестве терапевтических средств | |
| RU2010113980A (ru) | Применение с-пептида инсулина отдельно или в сочетании с glp-1 в качестве терапевтического средства | |
| RU2010114014A (ru) | Применение глюкагона (1-29) отдельно или в сочетании с нейропептидом w30 в качестве терапевтического средства | |
| RU2010114019A (ru) | Минигастрин в качестве терапевтического средства | |
| RU2010113984A (ru) | Применение врр-в в качестве терапевтического средства | |
| RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
| RU2010114005A (ru) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства | |
| RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства |